Sugi Predict

Sugi Predict / Targets / TLR4

TLR4

Toll-like receptor 4 · O00206 · TLR4 on Sugi Atlas →

32,576 patent compounds predicted against TLR4, 16,953 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL93754 SCHEMBL93754 1.00 19/20
SCHEMBL93755 SCHEMBL93755 0.86 19/20
Defoslimod Defoslimod (SCHEMBL132545) 0.75 18/20
SCHEMBL610334 SCHEMBL610334 0.79 16/20
SCHEMBL510139 SCHEMBL510139 1.00 14/20
SCHEMBL510140 SCHEMBL510140 1.00 14/20
SCHEMBL510207 SCHEMBL510207 1.00 13/20
SCHEMBL510208 SCHEMBL510208 1.00 13/20
SCHEMBL510377 SCHEMBL510377 1.00 12/20
SCHEMBL510378 SCHEMBL510378 1.00 12/20
SCHEMBL510102 SCHEMBL510102 0.66 12/20
SCHEMBL510103 SCHEMBL510103 0.66 12/20
SCHEMBL510290 SCHEMBL510290 0.56 12/20
SCHEMBL510291 SCHEMBL510291 0.56 12/20
SCHEMBL510517 SCHEMBL510517 0.75 11/20
SCHEMBL510592 SCHEMBL510592 0.66 11/20
SCHEMBL510593 SCHEMBL510593 0.66 11/20
SCHEMBL510714 SCHEMBL510714 1.00 10/20
SCHEMBL510715 SCHEMBL510715 1.00 10/20
SCHEMBL510268 SCHEMBL510268 0.74 10/20

Clinical trials — most relevant to TLR4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis PHASE3COMPLETED
Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic PHASE2/PHASE3WITHDRAWN
Treatment of Severe Infection With Antihyperlipidemia Drug PHASE2/PHASE3UNKNOWN
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia PHASE2COMPLETED
Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis PHASE2COMPLETED
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19 PHASE2UNKNOWN
The Effects of GLA on Human Volunteers PHASE1COMPLETED
Role of TLR4 in Environmental Asthma PHASE1COMPLETED
Mechanisms of Pain Hypersensitivity in a Human Skin Inflammation Model EARLY_PHASE1COMPLETED
the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia EARLY_PHASE1COMPLETED
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19 nanCOMPLETED
The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population nanRECRUITING
Role of TLR2 and TLR4 in Stage 2 Periodontitis Patients nanCOMPLETED
Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1 nanUNKNOWN
TLR4 Polymorphisms and Risk of Skin Cancer nanCOMPLETED
Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis nanCOMPLETED
The Genetics of Environmental Asthma nanCOMPLETED
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients nanCOMPLETED
TLR Polymorphism, ASO and Beta-hemolytic Group A Streptococcus Infections in ADHD: an Observational Study nanUNKNOWN
Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection nanCOMPLETED
The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis nanUNKNOWN
The Suppression of Toll Like Receptors by Insulin nanCOMPLETED
Expression of Toll-Like Receptors 2 and 4 in Asthmatic Patients. nanCOMPLETED
Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients nanCOMPLETED
MicroRNAs and Cytokines in Peri-Implantitis Tissue nanUNKNOWN
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis nanCOMPLETED
The Effect of Gut Sterilisation on Macrophage Activation in Patients With Alcoholic Hepatitis. nanCOMPLETED
Expression of Toll-like Receptors 3 , 7 and 9 in Peripheral Blood Mononuclear Cells of COVID-19 Patients nanUNKNOWN
Endotoxin Adsorber Hemoperfusion and Microcirculation nanCOMPLETED
Probiotics in the Prevention of Hepatocellular Carcinoma in Cirrhosis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TLR4 binder may also engage these)

ProteinNameSimilarity
Q8SPE8 — 1.000 Q8SPE8 →
Q9TTN0 — 1.000 Q9TTN0 →
Q9TSP2 — 1.000 Q9TSP2 →
Q9GL65 — 1.000 Q9GL65 →
P58727 — 1.000 P58727 →
Q2V898 — 1.000 Q2V898 →
Q9WV82 — 0.998 Q9WV82 →
Q9QX05 — 0.997 Q9QX05 →
Q8SPE9 — 0.997 Q8SPE9 →
Q9MYW3 — 0.997 Q9MYW3 →
Q68Y56 — 0.996 Q68Y56 →
Q6R5N8 — 0.996 Q6R5N8 →
Q9QUK6 — 0.995 Q9QUK6 →
Q0PV50 — 0.995 Q0PV50 →
TLR3 Toll-like receptor 3 0.994 landscape →
Q9JLF7 — 0.993 Q9JLF7 →
Q6R5P0 — 0.991 Q6R5P0 →
Q6AXL3 — 0.991 Q6AXL3 →
Q62192 — 0.991 Q62192 →
Q99467 — 0.989 Q99467 →
Q5M7S9 — 0.988 Q5M7S9 →
C0STK7 — 0.988 C0STK7 →
V5NAL9 — 0.986 V5NAL9 →
Q99MB1 — 0.986 Q99MB1 →
Q5TJ59 — 0.986 Q5TJ59 →
Q5BK65 — 0.986 Q5BK65 →
Q7Z2Q7 — 0.985 Q7Z2Q7 →
Q58A48 — 0.985 Q58A48 →
Q65YW8 — 0.984 Q65YW8 →
TLR5 Toll-like receptor 5 0.983 landscape →